These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 16330684)

  • 1. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
    Solomon SD; Anavekar N; Skali H; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Wang D; Pocock S; Pfeffer MA;
    Circulation; 2005 Dec; 112(24):3738-44. PubMed ID: 16330684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL; Nitsch D; Pfeffer MA; Swedberg K; McMurray JJ; Yusuf S; Granger CB; Michelson EL; Ostergren J; Cornel JH; de Zeeuw D; Pocock S; van Veldhuisen DJ;
    Circulation; 2006 Feb; 113(5):671-8. PubMed ID: 16461840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    O'Meara E; Clayton T; McEntegart MB; McMurray JJ; Piña IL; Granger CB; Ostergren J; Michelson EL; Solomon SD; Pocock S; Yusuf S; Swedberg K; Pfeffer MA;
    Circulation; 2007 Jun; 115(24):3111-20. PubMed ID: 17562950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
    Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Kenchaiah S; Pocock SJ; Wang D; Finn PV; Zornoff LA; Skali H; Pfeffer MA; Yusuf S; Swedberg K; Michelson EL; Granger CB; McMurray JJ; Solomon SD;
    Circulation; 2007 Aug; 116(6):627-36. PubMed ID: 17638930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
    O'Meara E; Clayton T; McEntegart MB; McMurray JJ; Lang CC; Roger SD; Young JB; Solomon SD; Granger CB; Ostergren J; Olofsson B; Michelson EL; Pocock S; Yusuf S; Swedberg K; Pfeffer MA;
    Circulation; 2006 Feb; 113(7):986-94. PubMed ID: 16476847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
    Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
    Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
    Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
    Eur J Heart Fail; 2007 May; 9(5):510-7. PubMed ID: 17317308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
    Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J;
    Lancet; 2003 Sep; 362(9386):777-81. PubMed ID: 13678871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
    Pocock SJ; McMurray JJ; Dobson J; Yusuf S; Granger CB; Michelson EL; Ostergren J; Pfeffer MA; Solomon SD; Anker SD; Swedberg KB
    Eur Heart J; 2008 Nov; 29(21):2641-50. PubMed ID: 18819960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of symptoms and signs of advanced heart failure and low left ventricle ejection fraction in patients after myocardial infarction with chronic heart failure].
    Kuch M; Janiszewski M; Janiszewski M; Braksator W; Mamcarz A; Sadkowska K; Kuch J; Dłuzniewski M
    Pol Merkur Lekarski; 2006 Mar; 20(117):285-8. PubMed ID: 16780256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
    Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
    Meredith PA; Ostergren J; Anand I; Puu M; Solomon SD; Michelson EL; Olofsson B; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; McMurray JJ
    J Am Coll Cardiol; 2008 Dec; 52(24):2000-7. PubMed ID: 19055992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Solomon SD; Wang D; Finn P; Skali H; Zornoff L; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pocock S; Pfeffer MA
    Circulation; 2004 Oct; 110(15):2180-3. PubMed ID: 15466644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.